ATLASMapLight Therapeutics (MPLT) earnings date: Dec 3, 2026
MapLight Therapeutics (MPLT) reports earnings for the quarter ended Sep 30, 2026 on Thu, Dec 3, 2026. Analysts expect EPS of -$1.22.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on MPLT
| Last price | $7.58 (-1.8%) |
|---|---|
| Normal 1-day range (±1σ) | ±5.1% |
| Earnings beat history | Beat the EPS estimate in 2 of the last 5 reports |
These figures come from the same calibrated model and valuation as the MapLight Therapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
MapLight Therapeutics reports on Dec 3, 2026. One email the day before, with ATLAS’s read on MapLight Therapeutics. You can switch it off at any time.
Alert me before MPLT reportsFree to start. Creating an account takes under a minute.
MPLT earnings at a glance
| Next report (confirmed) | Thu, Dec 3, 2026 |
|---|---|
| Time | Not stated |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$1.22 |
| Last report | Aug 13, 2026 · In line |
| Beat rate (last 5 reports) | 2 of 5 (40%) |
| Average EPS surprise | -24.2% |
| Average move around a report | ±2.7% (last 5) |
| Sector | Healthcare · Biotechnology |
MapLight Therapeutics earnings history: last 5 reports
MapLight Therapeutics last reported on Aug 13, 2026: EPS of -$1.32 against an estimate of -$1.31 (-0.8% surprise), in line with the estimate.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 13, 2026 | -$1.31 | -$1.32 | -0.8% | In line | +3.3% |
| Jul 20, 2026 | $0.34 | $0.36 | +5.9% | Beat | -1.1% |
| May 14, 2026 | -$1.09 | -$1.34 | -22.9% | Miss | -6.3% |
| Mar 26, 2026 | -$0.83 | -$2.47 | -197.6% | Miss | +2.3% |
| Feb 16, 2026 | -$10.85 | -$0.59 | +94.6% | Beat | +0.5% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for MPLT
See the fair value, the probability range and the earnings history of MapLight Therapeutics on its ATLAS page.
MapLight Therapeutics (MPLT) stock analysisPlans from €3.99 a month.
MapLight Therapeutics earnings: frequently asked questions
When does MapLight Therapeutics (MPLT) report earnings?
MapLight Therapeutics is scheduled to report on Thursday, December 3, 2026 (the time of day has not been stated). ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for MPLT?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$1.22 per share (USD). Estimates can change before the report.
How often does MPLT beat earnings estimates?
Of its last 5 reports with a recorded result, MapLight Therapeutics beat the EPS estimate 2 times; the average surprise was -24.2%. Past results do not predict the next one.
How much does MPLT move around earnings?
Over its last 5 reports the stock moved an average of 2.7% (absolute, from the close before the report day to the close after it), and finished higher 3 of 5 times.
Did MapLight Therapeutics beat earnings estimates last quarter?
MapLight Therapeutics last reported on Aug 13, 2026: EPS of -$1.32 against an estimate of -$1.31 (-0.8% surprise), in line with the estimate.
How much does MPLT usually move in a day?
On a normal trading day the ATLAS model puts MPLT’s one-day range at about ±5.1%, with a 49% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Thu, Dec 3, 2026
Educational information, not investment advice. Disclaimer